Clinical Research Directory

Inclusion Criteria: * Female patients aged 18 years or older * Overactive bladder symptoms for at least 3 months * Mirabegron 50 mg planned by physician decision within routine care * Ability to provide written informed consent Exclusion Criteria: * Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation) * Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection * Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease) * Active malignancy or cancer treatment within the last 5 years * Use of systemic glucocorticoids within the last 4 weeks, or chronic NSAID or immunosuppressive use * Conditions affecting lower urinary tract function other than OAB (neurogenic bladder, urinary tract stones, history of pelvic radiotherapy or bladder surgery, pelvic organ prolapse stage 3 or higher, or stress-predominant mixed urinary incontinence) * Known diagnosis of hematologic disease, anemia (Hb\<9), or platelet disorder (PLT\<100.000 or \>600.000) * Significant renal or hepatic impairment (eGFR below 30 mL/min/1.73 m2, or Child-Pugh class B or C) * Uncontrolled hypertension (180/110 mmHg or higher) or any other contraindication to mirabegron * Pregnancy or lactation * Major surgery or trauma within the last 3 months * Cognitive or functional inability to complete the voiding diary